Cannabis and cannabinoids as an alternative remedy in metabolic syndrome
DOI:
https://doi.org/10.1590/s2175-97902022e20161%20%20%20Keywords:
Cannabis, Cannabinoids, Metabolic syndrome, CB1 antagonists, Cannabidiol, Diabetes mellitusAbstract
Metabolic syndrome (MetS), an epidemic defined as a group of interconnected physiological, biochemistry, clinical, and metabolic factors, directly increases the risk of cardiovascular disease, atherosclerosis, type 2 diabetes, and death. MetS therapy includes diet, physical exercise, and a poly-pharmacological intervention. Cannabis is mainly recognized for its recreational uses and has several medical applications for neurological diseases, due to its hypnotic, anxiolytic, antinociceptive, anti-inflammatory, and anticonvulsant activities. Although several clinical observations in Cannabis smokers suggest metabolic effects, its utility in metabolic disorders is unclear. This review aims to determine under what conditions Cannabis might be useful in the treatment of MetS. Cannabis contains 120 phytocannabinoids, of which Δ9-THC mediates its psychoactive effects. Cannabinoids exert biological effects through interactions with the endocannabinoid system, which modulates several physiologic and metabolic pathways through cannabinoid receptors (CB1/CB2). Signaling through both receptors inhibits neurotransmitter release. In general, endocannabinoid system stimulation in Cannabis smokers and Δ9-THC signaling through CB1 have been implicated in MetS development, obesity, and type 2 diabetes. In contrast, CB1 antagonists and non-psychotropic phytocannabinoids like cannabidiol reduce these effects through interactions with both cannabinoid and non-cannabinoid receptors. These pharmacological approaches represent a source of new therapeutic agents for MetS. However, more studies are necessary to support the therapeutic potential of Cannabis and cannabinoids in metabolic abnormalities.
Downloads
References
Abramovici H. Cannabis (marihuana, marijuana) and the cannabinoids. Information for Health Care Professionals. Prepared by Health; 2018, pp. 8-12.
Abrams DI. The therapeutic effects of Cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report. Eur J Intern Med. 2018;49(3):7-11.
Abuhasira R, Shbiro L, Landschaft Y. Medical use of cannabis and cannabinoids containing products - Regulations on Europe and North America. Eur J Intern Med . 2018;49(3):2-6.
Aguilar S, Gutiérrez V, Sánchez L, Nougier M. Medicinal cannabis policies and practices around the world. International Drug Policy Consortium 2018; April:1-31. Accessed 25-April-2020.
Alshaarawy O, Anthony JC. Cannabis smoking and diabetes mellitus: Results from meta-analysis with eight independent replication samples. Epidemiology. 2015;26(4):597-600.
Alshaarawy O, Sidney S, Auer R, Green D, Soliman EZ, Goff, DC, et al. Cannabis use and markers of systemic inflammation: The coronary artery risk development in young adults study. Am J Med. 2019;132(11):1327-1334.e1.
Al-Zoubi R, Morales P, Regio PH. Structural insights into CB1 receptor biased signaling. Intern J Mol Sci. 2019;20(8):1873.1:24.
Argueta DA, DiPatrizio NV. Peropheral endocannabinoid signaling controls hyperphagia in western diet-induced obesity. Physiol Behav. 2017;171(3):32-39.
Atalay S, Jarocka-Karpowics I, Skrzydlewska E. Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants 2020;9(1):21.
Auer R, Sidney S, Goff D, Vittinghoff E, Pletcher MJ, Allen NB, et al. Lifetime marijuana use and subclinical atherosclerosis: The Coronary Artery Risk Development in Young Adults (CARDIA) study. Addiction. 2017;113(5):845-856.
Bian Y, He X, Jing Y, Wang L, Wang J, Xie X-Q. Computational systems pharmacology analysis of cannabidiol: a combination of chemogenomic-knowledgebase network analysis and integrated in silico modeling and simulation. Acta Pharm Sin. 2019;40(3):374-386.
Bielawiec P, Harasim-Symbor E, Chabowski A. Phytocannabinoids: useful drugs for the treatment of obesity? Special focus on cannabidiol. Front Endocrinol. 2020;11(3):114.
Bonini SA, Premoli M, Tambaro S, Kumar A, Maccarinelli G, Memo M, et al. Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history. J Ethnopharmacol. 2018;227(12):300-315.
Booth WT, Walker NB, Todd Lowther W, Howlett AC. Cannabinoid receptor interacting protein 1a (CRIP1a): Function and structure. Molecules. 2019;24(10):3672.
Borowska M, Czarnywojtek A, Sawicka-Gutaj N, Wolinski K, Plazinska MT, Mikolajzak P, et al. The effects of cannabinoids on the endocrine system. Endokrinol Pol. 2018;69(6):705-713.
Cassano T, Villani R, Pace L, Carbone A, Naik Bukke V, Orkisz S, et al. From Cannabis sativa to cannabidiol: Promising therapeutic candidate for the treatment of neurodegenerative diseases. Front Pharmacol. 2020;11(3):124.
Chacín M, Rojas J, Pineda C, Rodríguez D, Nuñez PM, Márques GM, et al. Human predisposition to the obesity, metabolic syndrome and diabetes: thrifty phenotype and the incorporation of the diabetic genes to the human genome from the biological anthropology. Sínd Cardiometab. 2011;1(1):11-24.
Chang E, Kim DH, Yang H, Lee DH, Bae SH, Park YP. CB1 receptor blockade ameliorates hepatic fat infiltration and inflammation and increases Nrf2-AMPK pathway in a rat model of severely uncontrolled diabetes. PLoS ONE. 2018;13(10):e0206152.
Chia ChW, Carlson OD, Liu D, González-Mariscal I, Calvo SSC, Egan JM. Incretin secretion in humans is under influence of cannabinoid receptors. Am J Physiol Endocrinol Metab. 2017;313(3):E359-E366.
Chorvat RJ. Peripherally restricted CB2 receptor blockers. Biorg Med Chem Lett. 2013;23(17):4751-4760.
Cinar R, Iyer MR, Kunos G. The therapeutic potential of second and third generation CB1 antagonists. Pharmacol Ther. 2020;208(4):107477.
Crepaldi G, Maggi S. Metabolic syndrome: Historical context. Diabetes Voice. 2006;51(1):8-10.
Di Marzo V, Piscitelli F, Mechoulam R. Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. In: Diabetes - Perspectives in Drug Therapy. M. Schwanstecher (ed.) Handbook of Experimental Pharmacology 203. Springer-Verlag Berling Heidelberg; 2011.
Di Marzo V, Silvestri C. Lifestyle and metabolic syndrome: Contribution of the endocannabinoidome. Nutrients. 2019;11(8):1956.
Farokhnia M, McDiamid GR, Newmeyer MN, Munjal V, Abulseoud OA, Huestis MA, et al. Effects of oral, smoked, and vaporized cannabis on endocrine pathways relates to appetite and metabolism: a randomized, double-blind, placebo-controlled, human laboratory study. Translational Psychiatry. 2020;10(1):71.
Fellous T, De Maio F, Kalkan H, Carannante B, Boccella S, Petrosino S, et al. Phytocannabinoids promote viability and functional adipogenesis of bone marrow-derived mesenchymal stem cells through different molecular targets. Biochem Pharmacol. 2020;175(2020):113859.1-13.
Fernandez-Lopez D, Lizasoain I, Moro MA, Martínez-Orgado J. Cannabinoids: Well-suited candidates for the treatment of perinatal brain injury. Brain Sci. 2013;3(3):1043-1059.
FICF. Fundació Institut Català de Farmacologia. Uso terapèutico del cannabis: Farmacología bàsica. Darrera Revisió: 12 Jan 2007 - 09:57. [http://Cannabis.icf.uab.es].
Finlay DB, Sircombe KJ, Kathleen J, Nimick M, Jones C, Glass M. Terpenoids from Cannabis do not mediate an entourage effect by acting at cannabinoid receptors. Front Pharmacol . 2020;11(3):359.
Fouda MA, Ghovanloo MR, Ruben PC. Cannabidiol protects against high glucose-induced oxidative stress and cytotoxicity in cardiac voltage-gated sodium channels. Br J Pharmacol. 2020;177(13):2632-2946.
Frisher M, White S, Varbiro G, Voisey C, Perumal D, Crome I, et al. The role of cannabis and cannabinoids in diabetes. Br J Diab Vasc Dis. 2010;10(12):267-273.
González-Mariscal I, Krzysik-Walker SM, Rouse M, Egan JM. Blockade of cannabinoid 1 receptor improves GLP-1R mediated insulin secretion in mice. Mol Cell Endocrinol. 2016a;423(3):1-10.
González-Mariscal I, Krzysik-Walker SM, Doyle ME, Liu Q-R, Cimbro R, Calvo SS-C, et al. Human CB1 receptor isoforms, present in hepatocytes and ß-cells, are involved in regulating metabolism. Sci Rep. 2016b;6(9):33302.1-12.
González-Mariscal I, Montoro RA, Doyle ME, Liu WR. Rouse M, O’Connell JF, et al. Absence of cannabinoid 1 receptor in beta cells protects against high-fat/high-sugar diet-induced beta cell dysfunction and inflammation in murine islets. Diabetologia. 2018;61(6):1470-1483.
Gruden G, Barutta F, Kunos G, Pacher P. Role of the endocannabinoid system in diabetes and diabetic complications. Br J Pharmacol . 2016;173(7):1116-1127.
Guillamat-Prats R, Rami M, Herzig S, Steffens S. Endocannabinoid signaling in atherosclerosis and related metabolic complications. Thromb Haem. 2019;119(4):567-575.
Gutiérrez-Rodríguez A, Itziar Bonilla-Del Río, Nagore Puente, Sonia M. Gómez-Urquijo, Christine J. Fontaine, Jon Egaña-Huguet, et al. Localization of the cannabinoid type-1 receptor in subcellular astrocyte compartments of mutant mouse hippocampus. Glia. 2018;66(7):1417-1431.
Hirao-Suzuki M, Takeda S, Koga T, Takiguchi M, Toda A. Cannabidiolic acid dampens the expression of cyclooxygenase-2 in MDA-MB-231 breast cancer cells: Possible implication of the peroxisome proliferator-activated receptor β/δ abrogation. J Toxicol Sci. 2020;45(4):227-236.
Hirsch S, Tam J. Cannabis: From a plant that modulates feeding behaviors towards developing selective inhibitors of the peripheral endocannabinoid system for the treatment of obesity and metabolic syndrome. Toxins (Basel). 2019;11(5):275.
Horvát B, Mukhopadhyay P, Haskó G, Pacher P. The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. Am J Pathol. 2012;180(2):432-442.
Howlett AC, Abood ME. CB1 & CB2 receptor pharmacology. Adv Pharmacol. 2017;80(6):169-206.
Hu Y, Tao Y, Hu J. Cannabinoid receptor 2 deletion deteriorates myocardial infarction through the down-regulation of AMPK-mTOR-p7026K signaling-mediated autophagy. Biosci Rep. 2019;39(4):BSR20180650.
Iannotti FA, Marzo DI, Petrosino S. Endocannabinoids and endocannabinoid. Relates mediators: Targets, metabolism and role in neurological disorders. Prog Lipid Res. 2016(4);62:107-128.
Ignatowska-Jankowska B, Jankowski MM, Swiergiel AH. Cannabidiol decreases body weight gain in rats: Involvement of CB2 receptors. Neurosci Lett. 2011;490(1):82-84.
Jadoon KA, Ratcliffe SH, Barrett DA, Thomas EL, Stott C, Bell JD, et al. Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel group pilot study. Diabetes Care. 2016;39(10):1777-1786.
Kalla A, Krishnamoorthy PM, Gopalakrishnan A, Figueredo VM. Cannabis use predicts risks of heart failure and cerebrovascular accidents: results from the National Inpatient Sample. J Cardiovasc Med (Hagerstown). 2018;19(9):480-484.
Katchan V, David P, Shoenfeld Y. Cannabinoids and autoimmune diseases: A systematic review. Autoimm Rev 2016;15(6):513-528.
Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;2014(3):943162.
Kuddus M, Ginawi IAM, Al-Hazimi A. Cannabis sativa: An ancient wild edible plant of India. Emir J Food Agric. 2013;25(10):736-745.
Laun AS, Shrader SH, Brown KJ, Song Z-H. GPR3, GPR6, and GPR12 as novel molecular targets: their biological functions and interaction with cannabidiol. Acta Pharmacol Sin. 2018;40(3):300-308.
Lazzari P, Sanna A, Mastinu A, Cabasino S, Manca I, Pani L. weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice. Behav Brain Res. 2011;217(2):432-438.
León OJ, Aguiar LG, Quevedo LA, Jara AB. Cardiovascular effects due to the use of cannabinoids. Rev Col Cardiol. 2018;25(3):230-235.
Li Ch, Bowe JE, Jones PM, Persaud SJ. Expression and function of cannabinoid receptors in mouse islets. Islets. 2010;2(5):293-302.
López-López AL, Bonilla-Jaime H, Brianza-Padilla M, Vázquez-Palacios G, Alarcon-Aguilar FJ. Chronic unpredictable mild stress progressively disturbs glucose metabolism and appetite hormones in rats. Acta Endocrinol (Buchar). 2018;14(1):16-23.
Madras BK. Update of Cannabis and its medical use. 37th ECDD (2015) Agenda item 6.2. World Health Organization; 2015, 41 p.
Martín GCM, Noriega SE, Kassuah DE, Fuentes LB, Manucha W. Anandamide and endocannabinoid system: an attractive therapeutic approach for cardiovascular disease. Ther Adv Cardiovasc Dis. 2018;12(7):177-190.
Martínez-Pinilla E, Varani K, Reyes-Resina I, Angelats E, Vincenzi F, Ferreiro-Vera C, et al. Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors. Front Pharmacol . 2017;8(10):744.
Mastinu A, Pira M, Pinna GA, Pisu C, Casu MA, Reali R, et al. NESS06SM reduces body weight with an improved profile relative to SR141716A. Pharmacol Res. 2013;74(8):94-108.
Mastinu A, Premoli M, Ferrari-Toninelli G, Tambaro S, Maccarinelli G, Memo M, et al. Cannabinoids in health and disease: Pharmacological potential in metabolic syndrome and neuroinflammation. Horm Mol Biol Clin Invest. 2018;36(2):20180013.
Mastinu A, Ribaudo G, Ongaro A, Bonini SA, Memo M, Gianoncelli A. Critical review on the chemical aspects of cannabidiol (CBD) and harmonization of computational bioactivity Data. Curr Med Chem. 2020;27(2): doi: 10.2174/0929867327666200210144847.
» https://doi.org/10.2174/0929867327666200210144847
McPartland JM. Cannabis systematics at the levels of family, genus, and species. Cann Cannabin Res. 2018;3(1):203-212.
McPartland JM, Guy GW, Di Marzo V. Care and feeding of the endocannabinoid system: A systematic review of the potential clinical interventions that upregulate the endocannabinoid system. PLoS ONE . 2014;9(3):e89566.
Meccariello R, Santoro A, DÁngelo S, Morrone R, Fasano S, Viggiano A, et al. The epigenetics of the endocannabinoid system. Int J Mol Sci. 2020;21(2):1113.
Monnerie S, Comte B, Ziegler D, Morais JA, Pujos-Guillot E, Gaudeau P. Metabolomic and lipidomic signatures of metabolic syndrome and its physiological components in adults: A systematic review. Sci Rep . 2020;10(1):669.
Muniyappa R, Sable S, Ouwerkerk R, Mari A, Gharib AM, Walter M. Metabolic effects of chronic cannabis smoking. Diabetes Care . 2013;36(8):2415-2422.
Nahtigal I, Blake A, Hand A, Florentinus-Mefailoski A, Hashemi H, Friedberg J. The pharmacological properties of cannabis. J Pain Manage. 2016;9(4):481-491.
Nava-Molina L, Uchida-Fuentes T, Ramos-Tovar H, Fregoso-Padilla M, Rodríguez-Monroy MA, Vega AV, et al. Novel CB1 receptor antagonist BAR-1 modifies pancreatic islet function and clinical parameters in prediabetic and diabetic mice. Nutr Diabetes. 2020;10(3):7.
Ngueta G. Impact of lifetime marijuana use on fasting plasma insulin levels and HOMA-IR score in obese adults with and without insulin resistance. Acta Diabetol. 2020;57(2):133-140.
Ngueta G, Ndjabouse R. Lifetime marijuana use in relation to insulin resistance in lean, overweight, and obese US adults. J Diabetes. 2020;12(1):38-47.
Nichols JM, Kaplan BLF. Immune responses regulated by cannabidiol. Cannabis Cannabinoid Res. 2020;5(1):12-31.
Okafor CN, Plankey MW, Goodman-Meza D, Li M, Bautista KJ, Bolivar H, et al. Association between self-reported marijuana use and incident diabetes in women and men with at risk for HIV. Drug Alcohol Depend. 2020;209(4):107935.
Ong KKL, Dunger DB. Thrifty genotypes and phenotype in the pathogenesis of type 2 diabetes mellitus. J Pediatr Endocrinol Metab. 2000;13(suppl 6):1419-1424.
Oyagawa CRM, de la Harpe SM, Saroz Y, Glass M, Vernall AJ, Grimsey NL. Cannabinoid receptor 2 signalling bias elicited by 2,4,6-trisubstituted 1,3,5-triazines. Front Pharmacol . 2018;9(10):1202.
Pazos RMR, Gandes MP. Cannabinoids and endocannabinoid system. Chapter 1. In: Therapeutic effects of cannabinoids. Ramos-Atance JA (coordinator). Instituto Universitario de Investigación en Neuroquímica de la Universidad Complutense de Madrid; 2017, pp. 1-23.
Penner EA, Buettner H, Mittleman MA. The impact of marijuana use on glucose, insulin, and insulin resistance among US adults. Am J Med . 2013;126(7):583-589.
Pepper I, Vinik A, Lattanzio F, McPheat W, Dobrian A. Countering the modern metabolic disease rampage with ancestral endocannabinoid system alignment. Front Endocrinol . 2019;10(5):311.
Pollastro F, Caprioglio D, Del Prete D, Rogati F, Minassi A, Taglialatela-Scafati O, et al. Cannabicromene. Nat Prod Commun. 2018;13(9):1189-1194.
Radwan MM, Wanas AS, Chandra S, ElSohly MA. Natural cannabinoids of Cannabis and methods of analysis. Chapter 7. In Cannabis sativa L. -Botany and Biotechnology. Chandra S, Lata H, ElSohly MA Ed. Springer; 2017, pp.161-82.
Rajavashisth TB, Shaheen M, Norris KC, Pan D, Sinha SK, Ortega J, et al. Decreased prevalence of diabetes in marijuana users: cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) III. BMJ Open. 2012;2(1):e000494.
Rajesh M, Mukhopadhyay P, Bátkai S, Patel V, Saito K, Matsumoto S. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol. 2010;56(25):2115-2125.
Ramos AJA, Fernández EJ. Endogenous cannabinoid system: ligands and receptors matched to transduction signals mechanisms. In: Monograph Cannabis Bobes J, Calafat A. Ed. Addictions 2000;12(2 suppl 2):59-81.
Remiszewski P, Jarocka-Karpowicz I, Biernacki M, Jastrzab A, Schlicker E, Toczek M, et al. Chronic cannabidiol administration fails to Diminish blood pressure in rats with primary and secondary hypertension despite its effects on cardiac and plasma endocannabinoid system, oxidative stress and lipid metabolism. Int J Mol Sci . 2020;21(4):1295.
Roberts CA, Jager G, Christiansen P, Kirkham TC. Exploring the munchies: An online survey of users’ experiences of cannabis effects on appetite and the development of a Cannabinoid Eating Experience Questionnaire. J Psychopharmacol. 2019;33(7):1149-1159.
Rock EM, Sticht MA, Duncan M, Stott C, Parker LA. Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ9-tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats. Br J Pharmacol . 2013;170(3):671-678.
Ross JM, Pacheco-Colón I, Haws SW, Gonzalez R. Bidirectional longitudinal associations between Cannabis use and body mass index among adolescents. Cannabis Cannabinoid Res . 2020;5(1):81-88.
Scharf EL. Translating endocannabinoid biology into clinical practice: Cannabidiol for stroke prevention. Cannabis Cannabinoid Res . 2017;2(1):259-264.
Shin H, Yoon J, Sim HJ, Park TJ, Yang S, Lee K, et al. Blockade of cannabinoid 1 receptor improves glucose responsiveness in pancreatic beta cells. J Cell Mol Med. 2018;22(4):2337-2345.
Sidibeh CO, Perreira MJ, Börjesson JL, Kambe PG, Skrtic S, Katsogiannos P, et al. Role of cannabinoid receptor 1 in human adipose tissue for lipolysis regulation and insulin resistance. Endocrine. 2017;55(3):839-852.
Simon V, Cota D. Endocannabinoids and metabolism: Past, present and future. Eur J Endocrinol. 2017;176(6):R309-R-324.
Smeriglio A, Giofrè SV, Galati EM, Monforte MT, Cicero N, Dángelo V, et al. Inhibition of aldose reductase activity by Cannabis sativa chemotypes extracts with high content of cannabidiol or cannabigerol. Fitoterapia. 2018;127(6):101-108.
Stanley ChP, Wheal AJ, Randall MD, O´Sullivan SE. Cannabinoids alter endothelial function in the Zucker rat model of type 2 diabetes. Eur J Pharmacol. 2013;720(1-3):376-382.
Tam J, Hinden L, Dori A, Udi S, Azar S, Baraghithy S. Therapeutic potential of targeting the peripheral endocannabinoid/CB1 receptor system. Eur J Intern Med . 2018;49(3):23-29.
Tarragon E, Moreno JJ. Role of endocannabinoids on sweet taste perception, food preference, and obesity-related disorders. Chem Sci. 2018;43(1):3-16.
Thompson ChA, Hay JW. Marijuana use in models for health outcomes. Am J Med . 2015;128(3):e23.
Tibiriça E. The multiple functions of the endocannabinoid system: a focus on the regulation of food intake. Diabetol Metab Syndr. 2010;2(1):5.
Ukkola O. Ghrelin in type 2 diabetes mellitus and metabolic syndrome. Mol Cell Endocrinol . 2011;340(1):26-28.
Valenzuela C, Aguirre C, Castillo V, Ronco AM, Llanos M. A role for the endocannabinoid system in obesity. Rev Med Chile. 2010;138(1):621-629.
Van Eenige R, van der Stelt M, Rensen PCN, Kooijman S. Regulation of adipose tissue metabolism by the endocannabinoid system. Trends Endocrinol Metab. 2018;29(5):326-337.
Vanita P, Jhansi K. Metabolic syndrome in endocrine system. J Diab Metab. 2011;2(9):163.
Vecera L, Gabrhelik T, Prasil P, Stourac P. The role of cannabinoids in the treatment of cancer. Brattish Med J. 2020;121(1):79-95.
Vidot DC, Prado G, Hlaing WWM, Florez HJ, Arheart KL, Messiah S. Metabolic syndrome among marijuana users in the United States: An analysis of National Health and Nutrition Examination Survey data. Am J Med . 2016;129(2):173-179.
Vilches-Flores A, Hauge-Evans AC, Jones PM, Persaud SJ. Chronic activation of cannabinoid receptors in vitro does not compromise mouse islet function. Clin Sci. 2013;124(7):467-478.
Vong CT, Ling Tseng HH, Kwan YW, Lee SM-Y, Man Hoi MP. Novel protective effect of O-1602 and abnormal cannabidiol, GPR55 agonists, on stress-induced apoptosis in pancreatic ß-cells. Biomed Pharmacother. 2019;111(3):1176-1186.
WHO. World Health Organization-40th Expert Committee on Drug Dependence Pre-Review. Delta-9-tetrahydrocannabinol Section 1: Chemistry; 2018, pp. 1-33.
Zhang X, Gao S, Niu J, Li P, Deng J, Xu S, et al. Cannabinoid 2 receptor agonist improves systemic sensitivity to insulin in high-fat diet/streptozotocin-induced diabetic mice. Cell Physiol Biochem. 2016;40(5):1175-1185.
Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. Intern J Mol Sci. 2018;19(3):1-23.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
